MANNOS, a pioneering brand in the global oral probiotic sector, has always centered its mission on scientific innovation. With deep expertise in oral health, the brand is committed to delivering professional, safe oral and respiratory health solutions for the whole family. In 2023, MANNOS took the lead in establishing an in-depth strategic cooperation with BLIS, a renowned New Zealand probiotic enterprise. It officially introduced oral probiotic products based on the core strains K12 and M18 into the Chinese market, filling the gap in the domestic high-end oral probiotic segment. Meanwhile, the brand rapidly completed omnichannel deployment, building a diversified sales network covering mainstream online platforms, professional dental institutions, medical channels, chain pharmacies and maternal & baby specialty channels, making premium products accessible to more consumers. Backed by strong product capabilities and industry influence, MANNOS has participated in major authoritative exhibitions such as the China International Dental Exhibition and the China International Import Expo, fully showcasing its core technologies and product advantages, and earning wide recognition from industry peers and consumers. As one of the drafting units for the China Oral Probiotic Group Standard jointly initiated by top domestic dental institutions including West China Hospital of Stomatology, the National Key Laboratory of Oral Diseases, and Shanghai Ninth People’s Hospital, MANNOS actively contributes to formulating industry standards and driving the standardized, scientific development of the oral probiotic field. In 2026, MANNOS once again leads industry innovation by pioneering the concept of the “2.0 Era of Respiratory & Oral Probiotics”. It selects three core imported raw materials—BLIS strains, L8020 strains, and New Zealand Manuka honey powder—to form a robust strain matrix. Through scientific formulation, L8020 is optimally combined with K12/M18 and premium New Zealand Manuka honey, creating a triple-care system of “K12/M18 + L8020 + Manuka honey” that delivers true synergistic benefits of 1+1+1＞3, comprehensively safeguarding oral and respiratory health. Products are manufactured at a probiotic production facility meeting Asia’s highest standards, with the enterprise holding authoritative certifications including FDA GRAS, HACCP, HALAL, and EAC (Eurasian Conformity). Full-process traceability ensures products are pure, safe, and potent, maximizing the efficacy of each ingredient. Beyond core probiotic products, MANNOS also introduces New Zealand Egmont Manuka honey as an independent premium product. Sold in over 30 countries worldwide, it holds the No.1 market share in the United States and Australia. Sourced from the pristine rainforests of South Taranaki, New Zealand, it is certified by both UMF and MGO, free of pesticide residues and non-GMO, preserving natural active compounds. Its quality is globally acclaimed, especially the rare premium UMF25+ grade, whose active ingredient content far exceeds that of ordinary Manuka honey—making it a rare treasure in the high-end Manuka honey segment and a superior choice for consumers pursuing a natural, healthy lifestyle. Looking ahead, MANNOS will continue to deepen its focus on oral and respiratory health. Driven by technological innovation and underpinned by quality service, it strives to address a wide range of oral and respiratory concerns for families worldwide, aiming to become a leading global brand in oral probiotics and safeguard the oral health of every consumer.